Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression

Detalhes bibliográficos
Autor(a) principal: Vaezi, Maryam
Data de Publicação: 2018
Outros Autores: Yaghmaei, Parichehreh, Hayati-Roodbari, Nasim, Irani, Shiva, Ebrahim-Habibi, Azadeh
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Pharmaceutical Sciences
Texto Completo: https://www.revistas.usp.br/bjps/article/view/153861
Resumo: Citral is a small molecule present in various citrus species, with reported anti-hyperlipidemic and antiinflammation effects. Here, the effect of intraperitoneal (IP) administration of citral is evaluated in a mouse model of non-alcoholic steatosis. Male NMRI mice were divided into the following groups (n = 12): normal control group (NC) receiving a normal diet; high-fat emulsion group (HF) receiving high fat diet for four weeks; positive control group (C+) receiving HF diet for four weeks and then shifted to normal diet with IP-administered silymarin (80 mg/kg) for four weeks; sham group receiving HF diet for four weeks and then shifted to normal diet for four weeks; and EC1, EC2, and EC3 groups receiving HF diet for four weeks and then shifted to normal diet with IP-administered citral doses of 5, 10, and 20 mg/kg, respectively. HF diet resulted in steatohepatitis with impaired lipid profile, high glucose levels and insulin resistance, impaired liver enzymes, antioxidants, adiponectin and leptin levels, decreased PPARα level, and fibrosis in the liver tissue. Upon treatment with citral, improvement in condition was observed in a dose-dependent manner—both at histological level and in the serum of treated animals. and the PPARα level was also increased.
id USP-31_b6495ea1a6611a5b731bae6fcb16d88c
oai_identifier_str oai:revistas.usp.br:article/153861
network_acronym_str USP-31
network_name_str Brazilian Journal of Pharmaceutical Sciences
repository_id_str
spelling Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expressionCitral effectsLemonalLiver diseaseSilymarinCitral is a small molecule present in various citrus species, with reported anti-hyperlipidemic and antiinflammation effects. Here, the effect of intraperitoneal (IP) administration of citral is evaluated in a mouse model of non-alcoholic steatosis. Male NMRI mice were divided into the following groups (n = 12): normal control group (NC) receiving a normal diet; high-fat emulsion group (HF) receiving high fat diet for four weeks; positive control group (C+) receiving HF diet for four weeks and then shifted to normal diet with IP-administered silymarin (80 mg/kg) for four weeks; sham group receiving HF diet for four weeks and then shifted to normal diet for four weeks; and EC1, EC2, and EC3 groups receiving HF diet for four weeks and then shifted to normal diet with IP-administered citral doses of 5, 10, and 20 mg/kg, respectively. HF diet resulted in steatohepatitis with impaired lipid profile, high glucose levels and insulin resistance, impaired liver enzymes, antioxidants, adiponectin and leptin levels, decreased PPARα level, and fibrosis in the liver tissue. Upon treatment with citral, improvement in condition was observed in a dose-dependent manner—both at histological level and in the serum of treated animals. and the PPARα level was also increased.Universidade de São Paulo. Faculdade de Ciências Farmacêuticas2018-11-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/bjps/article/view/15386110.1590/s2175-97902018000317596Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 3 (2018); e17596Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 3 (2018); e17596Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 3 (2018); e175962175-97901984-8250reponame:Brazilian Journal of Pharmaceutical Sciencesinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/bjps/article/view/153861/150217Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)info:eu-repo/semantics/openAccessVaezi, MaryamYaghmaei, ParichehrehHayati-Roodbari, NasimIrani, ShivaEbrahim-Habibi, Azadeh2019-03-17T13:18:22Zoai:revistas.usp.br:article/153861Revistahttps://www.revistas.usp.br/bjps/indexPUBhttps://old.scielo.br/oai/scielo-oai.phpbjps@usp.br||elizabeth.igne@gmail.com2175-97901984-8250opendoar:2019-03-17T13:18:22Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
title Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
spellingShingle Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
Vaezi, Maryam
Citral effects
Lemonal
Liver disease
Silymarin
title_short Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
title_full Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
title_fullStr Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
title_full_unstemmed Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
title_sort Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
author Vaezi, Maryam
author_facet Vaezi, Maryam
Yaghmaei, Parichehreh
Hayati-Roodbari, Nasim
Irani, Shiva
Ebrahim-Habibi, Azadeh
author_role author
author2 Yaghmaei, Parichehreh
Hayati-Roodbari, Nasim
Irani, Shiva
Ebrahim-Habibi, Azadeh
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Vaezi, Maryam
Yaghmaei, Parichehreh
Hayati-Roodbari, Nasim
Irani, Shiva
Ebrahim-Habibi, Azadeh
dc.subject.por.fl_str_mv Citral effects
Lemonal
Liver disease
Silymarin
topic Citral effects
Lemonal
Liver disease
Silymarin
description Citral is a small molecule present in various citrus species, with reported anti-hyperlipidemic and antiinflammation effects. Here, the effect of intraperitoneal (IP) administration of citral is evaluated in a mouse model of non-alcoholic steatosis. Male NMRI mice were divided into the following groups (n = 12): normal control group (NC) receiving a normal diet; high-fat emulsion group (HF) receiving high fat diet for four weeks; positive control group (C+) receiving HF diet for four weeks and then shifted to normal diet with IP-administered silymarin (80 mg/kg) for four weeks; sham group receiving HF diet for four weeks and then shifted to normal diet for four weeks; and EC1, EC2, and EC3 groups receiving HF diet for four weeks and then shifted to normal diet with IP-administered citral doses of 5, 10, and 20 mg/kg, respectively. HF diet resulted in steatohepatitis with impaired lipid profile, high glucose levels and insulin resistance, impaired liver enzymes, antioxidants, adiponectin and leptin levels, decreased PPARα level, and fibrosis in the liver tissue. Upon treatment with citral, improvement in condition was observed in a dose-dependent manner—both at histological level and in the serum of treated animals. and the PPARα level was also increased.
publishDate 2018
dc.date.none.fl_str_mv 2018-11-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/bjps/article/view/153861
10.1590/s2175-97902018000317596
url https://www.revistas.usp.br/bjps/article/view/153861
identifier_str_mv 10.1590/s2175-97902018000317596
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/bjps/article/view/153861/150217
dc.rights.driver.fl_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2018 Brazilian Journal of Pharmaceutical Sciences (Impresso)
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Ciências Farmacêuticas
dc.source.none.fl_str_mv Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 3 (2018); e17596
Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 3 (2018); e17596
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 3 (2018); e17596
2175-9790
1984-8250
reponame:Brazilian Journal of Pharmaceutical Sciences
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Brazilian Journal of Pharmaceutical Sciences
collection Brazilian Journal of Pharmaceutical Sciences
repository.name.fl_str_mv Brazilian Journal of Pharmaceutical Sciences - Universidade de São Paulo (USP)
repository.mail.fl_str_mv bjps@usp.br||elizabeth.igne@gmail.com
_version_ 1800222913804107776